Background: Radiotherapy is a mainstay for the treatment of lung cancer that can induce pneumonitis or pulmonary fibrosis. The matricellular protein connective tissue growth factor (CTGF) is a central mediator of tissue remodeling. Methods: A radiation-induced mouse model of pulmonary fibrosis was used to determine if transient administration of a human antibody to CTGF (FG-3019) started at different times before or after 20 Gy thoracic irradiation reduced acute and chronic radiation toxicity. Mice (25 mice/group; 10 mice/group in a confirmation study) were examined by computed tomography, histology, gene expression changes, and for survival. In vitro experiments were performed to directly study the interaction of CTGF blockade and radiation. All statistical tests were two-sided. Results: Administration of FG-3019 prevented (50%-80%) or reversed (50%) lung remodeling, improved lung function, improved mouse health, and rescued mice from lethal irradiation (P < .01). Importantly, when antibody treatment was initiated at 16 weeks after thoracic irradiation, FG-3019 reversed established lung remodeling and restored lung function. CTGF blockade abrogated M2 polarized macrophage influx, normalized radiation-induced gene expression changes, and reduced myofibroblast abundance and Osteopontin expression. Conclusion: These results indicate that blocking CTGF attenuates radiation-induced pulmonary remodeling and can reverse the process after initiation. CTGF has a central role in radiation-induced fibrogenesis, and FG-3019 may benefit patients with radiation-induced pulmonary fibrosis or patients with other forms or origin of chronic fibrotic diseases.
Key mediators of lung fibrosis have been identified, but a unified model of fibrogenesis has not been established (12, 13) . A number of treatment strategies have shown promising effects in rodent models of lung toxicity, including targeting free radical production (14) , inflammatory cell recruitment, statins, and inhibitors of PDGF, VEGF, FGF, TGFß, Cox-2, integrin signaling (6, 7, (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) , and targeting the TLR-4, CXCL12/CXCR4-axis, and NADPH-Oxidase 4 (28) . The effectiveness of agents to halt fibrosis or reverse manifested lung remodeling in the clinic has yet to be investigated (29) (30) (31) (32) (33) .
The matricellular protein connective tissue growth factor (CTGF) is a central mediator of tissue remodeling and fibrosis (34) (35) (36) (37) . CTGF has been reported to be an essential mediator for the fibrotic activity of TGFb (38, 39) , but can also act independently of TGFb. A role of CTGF expression has been described in mouse models of bleomycin-induced pulmonary fibrosis (40) (41) (42) (43) , and elevated CTGF expression was reported in patients with IPF (44) (45) (46) (47) (48) .
Here we investigated whether blocking CTGF with FG-3019, a human monoclonal antibody that binds human and rodent CTGF, could attenuate and reverse pulmonary fibrosis after thoracic irradiation. The C57Bl/6 lung radiation model used is physiologically relevant because it exhibits a similar slow, progressive course and mechanisms characteristic of human fibrosis (1, (49) (50) (51) . Strong biphasic induction of CTGF expression in the lungs of irradiated C57Bl/6 mice has also been reported (50) . FG-3019 was evaluated prior to observation of persistent lung remodeling (prevention) and after statistically significant lung remodeling was detectable (therapeutic intervention) (51) .
Methods

Mouse Thorax Irradiation and CT Monitoring
All animal and cell procedures were approved by institutional and governmental authorities (DKFZ internal animal protection office; Regierungspraesidium Karlsruhe, Germany). Irradiation and monitoring of the six-to eight-week-old female C57Bl/6 mice (25 mice/group; 10 mice/group in a confirmatory study) were performed as previously described (15, 52) . Mice thoraces were irradiated with 20 Gy photons (6 MeV linac, dose rate 118 cGy/min, Siemens, Munich, Germany) (Supplementary Figure 1 , available online). High-resolution computed tomography (HRCT; Aquilion, Toshiba, Minato, Japan) was analyzed for morphological and quantitative lung density. For the irradiation and CT procedures, mice were anesthetized by intraperitoneal application of 0.2 mg/kg Rompun (Bayer, Leverkusen, Germany) and 100 mg/kg ketamine 10% (Parke-Davis, Detroit, MI).
Antibody Treatment
FG-3019 is a human mAb and was administered (i.p., 10mg/kg, 3/week) for eight weeks starting two days before irradiation (pretreatment group), or two, 20, or 112 days (16 weeks) after irradiation (two-, 20-or 112-day groups). Control (nonirradiated) mice received FG-3019 or IgG for eight weeks beginning two days after experiment initiation. Placebo-treated mice received IgG for eight weeks beginning two days after irradiation. Antibodies were provided by Fibrogen, Inc. (San Francisco, CA) in histidine-buffered saline, pH 6.
Lung Histology
Histological analysis was performed as previously described (15, 52) . In brief, two to four mice/group were killed for histology on days scheduled for CT examination. Their lungs were fixed by intratracheal instillation of 4% formalin followed by overnight fixation, embedded in paraffin, sectioned at 5 mm, and stained with hematoxylin and eosin (H&E) or Sirius red for collagen deposition. Alpha-SMA staining was performed using Vector Elite Stain Kits (pk6101, Vector, Burlingame, CA) and an anti-aSMA-antibody (Abcam 5694-100; Abcam, Cambridge, UK). Macrophages were detected by a monoclonal rat antibody (Abcam, ab56297), and mastcells were stained by Giemsa (Dako, Hamburg, Germany). Visualization was performed using biotinylated secondary antibodies followed by an avidin-biotin peroxidase complex (Vectastain, PK6100; Vector, Burlingame, CA) and the chromogen 3,3'-diaminobenzidine (Vectastain, PK6100). Images were captured using a Nikon Eclipse E600 microscope equipped with a Nikon digital sight DS-U1 (Nikon Corp., Chiyoda, Tokyo, Japan) and analyzed with ImageJ Software Version 1.42q (National Institutes of Health, Bethesda, MD).
Health Status in Mice and Blood Gas Analysis
Blood was collected from the tail capillary of three mice/group, and oxygen content was measured on an ABL5 Radiometer blood gas analyzer (Radiometer GmbH, Willich, Germany). Mouse health was assessed semiquantitatively in at least three randomly chosen mice using a rank scale (0-3) assessing mobility, skin status, hunched back, breath rate, and weight.
Gene Expression in Mouse Lungs
RNA from two mice per group was quantified on one-color 4x44K mouse whole genome arrays (Agilent G4122F; Agilent, Santa Clara, CA). Array data were analyzed with Genespring GX (Agilent) software. Data were normalized to the median of eight nonirradiated control samples. Major expression patterns of probes altered substantially (twofold) and statistically significantly (P < 0.01) by irradiated (RT) relative to nonirradiated IgG controls or FG-3019 relative to RT alone were identified by principal components analysis. Cell type-specific origins of coordinately altered transcripts were confirmed using the mouse BioGPS database. All fold-change (Fc) values used for individual comparison between two groups met cutoffs for a greater than twofold increase or decrease in relative expression, calculated as the relative expression between the two groups. Data are available at ArrayExpress (accession number: E-TABM-1153).
In Vitro Assays
Primary isolated human endothelial and fibroblast cells (HUVEC, HDMEC), human pulmonary fibroblasts (HPF), normal human dermal fibroblasts (NHDF), primary human mesenchymal stem cells (MSC) (53) , and human NSCLC A549 cells were treated with FG-3019 6 radiation. Clonogenic, cell proliferation, and Matrigel invasion/migration and proliferation coculture assays were performed. Immunoblots were probed with FG-3019, anti-aSMA, anti-collagen IV antibodies. Cell cycle and apoptosis assays using subG1 DNA and Caspase-3 were performed by FACS. 
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Mouse survival curves after thoracic irradiation and antibody treatments were calculated with the Kaplan-Meier method and analyzed using the log-rank test and the Cox proportional hazards model. The assumption of proportionality was verified by including time-dependent covariates in the Cox model and also by analyzing the Kaplan-Meier curves. Starting points for the log-rank test were the time of radiation or the time of FG-3019 start, as indicated. Mice killed for histological examination were censored. Other quantitative data are shown as mean values 6 SD, as indicated. For analysis of differences between multiple groups, analysis of variance (ANOVA) was used, followed by the appropriate post hoc test. Expression data were analyzed using ANOVA with Bonferroni correction. Student's t test was used for parametric and Wilcoxon test for nonparametric variables. Correlation analyses were performed using Pearson correlation coefficient (PCC). All tests were two-tailed. P values of less than .05 were considered statistically significant. The Graphpad Prism (Version 6.0, Ja Jolla, CA) and Statistica (Statistica 5.0, Statsoft, Tulsa, OK) software packages were used.
For detailed methods, please refer to the Supplementary Materials and Methods (available online).
Results
Survival and Mouse Health after Lethal Thorax Irradiation
Thoracic irradiation without FG-3019 treatment was uniformly lethal and all mice died within 11 months, while transient FG-3019 treatment prolonged overall survival in a scheduledependent manner (Figure 1, A-D) . FG-3019 extended median survival of irradiated mice from 161 days (95% CI ¼ 151.1 to 170.9) to 300 days (95% CI ¼ 166.1 to 325.9; P ¼ .003 for pooled, FG-3019-treated mice) ( Figure 1B ). The greatest survival benefit was achieved when FG-3019 treatment was initiated 20 days after irradiation with 70% survival at 48 weeks (P ¼ .01) ( Figure  1C ). Initiation of FG-3019 two days before irradiation also increased survival (P ¼ .03). The survival advantage from FG-3019 was present if data were analyzed from the time of radiotherapy or from the start of treatment ( Figure 1D ). FG-3019 was well tolerated and improved the health of irradiated mice ( Figure 1E ; Supplementary Table 1, available online). Mice in the 20-day group showed the greatest benefits and were most similar to nonirradiated control mice. Mice that started FG-3019 at 16 weeks after irradiation, when health deterioration was already evident, showed statistically significant and persistent health status improvement during the eight weeks of FG-3019 administration and after treatment was completed (Supplementary Table 1 , available online). Irradiated mice (RT) and placebotreated mice exhibited reduced weight vs controls (P < .001). FG-3019-treated groups attenuated the radiation-associated weight loss (P ¼ .008 vs RT).
Computed Tomography of Lung Density Increases
A hallmark of lung fibrosis is increased tissue density, which is the basis of computed tomography (CT) analysis. Longitudinal CT monitoring demonstrated that the lung density of irradiated mice progressively increased after 12 weeks until 30 weeks ( Figure 2 , A-C). By eight weeks, CT morphology revealed highdensity foci distributed throughout the lungs as typical signs of acute and subacute pneumonitis. By week 30, these dense foci fused to larger areas, indicative of chronic radiation damage and lung fibrosis. Reticular alterations and irregular septal thickening were typical CT findings characteristic of pulmonary fibrosis, consistent with histology. FG-3019 reduced CT signs of damage and lung densities. Early FG-3019 treatment attenuated the lung density increase by 42.8% (FG-3019 pre) and 46.5% (FG-3019 post day 2). FG-3019 initiation at day 20 almost completely prevented radiologically detectable lung damage, attenuated lung density increase by 83.3% (week 48 postirradiation), and yielded CT images comparable with nonirradiated control mice.
CT imaging also demonstrated that the lung density increase was reversible upon CTGF blockade: At 16 weeks, lung density was increased by 100 HU in irradiated mice without FG-3019 and continued to rise thereafter. FG-3019 administration starting at 16 weeks induced progressive lung density decreases that remained stable after treatment ceased ( Figure 2C ).
Lung and chest wall radiation-induced toxicity can alter the macroscopic structure and morphology of the thoracic scaffolding, leading to reduced lung size, mobility, and function. CT data revealed that FG-3019 also attenuated radiation-induced thorax shrinkage and cardiac hypertrophy 
Lung Function
In radiotherapy of lung cancer patients, a major side effect is worsening of lung function resulting in reduced blood oxygenation (3). We assessed gas exchange from tail capillary blood for oxygen partial pressure (paO 2 ). At 30 weeks, paO 2 levels were substantially below normal, indicating worsening of the oxygen status, while paO 2 values in the 20-day/16-week FG-3019 groups were in the normal range, indicating a positive effect on lung function ( Figure 2D ). In addition, the oxygen saturation data inversely correlated with lung densities measured by CT (r 2 ¼ 0.80, P < .001) ( Figure 2E ). Thus, FG-3019 robustly improved function of irradiated lungs in a treatment-and schedule-sensitive manner, and CT lung density measurements were representative of lung function. For details, see the Supplementary Results (available online). Shows the pooled data of irradiated mice with no FG-3019 treatment vs the pooled data of the four irradiated groups treated with FG-3019 (P ¼ .002, Cox regression). C) Shows the eight individual groups with median survival. If more than 50% of the mice at risk per group were still alive at the end of the experiment (48 weeks after irradiation), median survival is indicated as more than 336 days. D) Kaplan-Meier survival curves with the respective starting points at the time of FG-3019 treatment start.
Lung and Cardiac Remodeling
E) Body weights of mice, as a general measure of health status. Bars are mean 6 SD. All statistical tests were two-sided. RT ¼ irradiated.
ARTICLE online). Consistent late changes included alterations in the epithelium of bronchi and bronchioles including erosion, hyperplasia, and squamous metaplasia. By 30 weeks, extensive lung remodeling had occurred and morphometric analysis indicated that only approximately 30% of the alveolar area remained intact. Sirius Red staining revealed fibrotic patches of collagen, consistent with irradiation-induced fibrogenesis ( Figure 3A ). FG-3019 strongly reduced erosion, wall broadening, collagen deposition, and fibrosis in a schedule-dependent manner: The strongest beneficial effects of FG-3019 were seen in the 20-day group, which exhibited minimal change throughout the course of the experiment, and lungs that looked histologically normal at 30 weeks-more than two months after FG-3019 administration had halted.
In the 16-week group, septal thickening and pneumonitis were evident at 16 weeks, but lung remodeling was substantially resolved within two weeks of FG-3019 treatment and almost completely resolved by 24 weeks (Figure 3 , B and D; Supplementary Results and Supplementary Figure 3 , available online). Thus radiology and histology showed that FG-3019 robustly improved lung fibrosis-associated parameters and suggested that as little as two weeks of FG-3019 reversed delayed radiation-induced lung toxicity.
Furthermore, alpha-smooth muscle actin (aSMA) staining at 30 weeks showed that FG-3019 reduced irradiation-induced myofibroblast abundance ( Figure 3E ) as a potential mechanism for FG-3019's antifibrotic effects because myofibroblasts are involved in ECM deposition and lung remodeling in lung fibrosis (54) . Likewise CTGF blockade between 16 and 18 weeks markedly reversed radiation-induced osteopontin/SPP1 mRNA and protein expression ( Figure 3F ), which is a potential biomarker for the development of pulmonary fibrosis (55) (56) (57) .
Histology of the hearts revealed collagen deposits indicating mild myocardial fibrosis of both the right (RV) and left (LV) ven- 
Acute Inflammation and Edema
FG-3019 pretreatment prevented leukocyte infiltration at day 2 ( Figure 4A ; Supplementary Results, available online), consistent with a report of CTGF affecting peripheral blood mononuclear cells (PBMC) recruitment (58, 59) . FG-3019 also suppressed acute septal thickening, a surrogate for interstitial edema ( Figure 4A ; 
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Supplementary Figure 5A, available online) . This is relevant because edema allows extravascular fibrin to serve as a provisional matrix, promoting epithelial-to-mesenchymal transition (EMT) in response to stimuli like TGFb (60) leading to formation of myofibroblasts. Together the data suggest a role for CTGF in radiation-induced acute edema and leukocyte influx (Supplementary Figure 7 , available online).
Delayed Immune Response
The acute inflammation and edema spontaneously subsided by two weeks after irradiation. A subsequent inflammation phase reached a fourfold higher leucocyte peak at 18 to 20 weeks ( Figure 4B ; Supplementary Figure 5B , available online). FG-3019 reduced alveolar histiocytosis, characterized by sharp increases of macrophages and mast cells after 16 weeks (Figure 4, C and  D) . In the 16-week group, two weeks of FG-3019 reversed and prevented pulmonary leukocyte influx. Between 16 weeks and 18 weeks after irradiation, the relative percentage of macrophages increased disproportionally from 2.9% 6 0.29% to 34.1% 6 3.3% of all leukocytes (P ¼ .003). FG-3019 reduced the macrophage influx and prevented this proportion shift, suggesting that macrophage influx drives fibrogenic lung remodeling in response to irradiation ( Figure 4E ).
Gene Expression Changes
Microarray analysis was performed to better understand reversal of the fibrotic process. Microarray expression profiling on 18-week lung samples (n ¼ 2/group) showed that the expression of many transcripts was statistically significantly, substantially, and coordinately altered by radiation alone ( Figure 5A ). FG-3019 beginning 20 days or 16 weeks after irradiation produced a gene expression pattern resembling that of nonirradiated mice. This expression normalization in the 16-week therapeutic group suggested that inhibition of CTGF for only two weeks was sufficient to profoundly alter the biology of the remodeling lung. Analysis of individual genes showed that radiation increased transcripts associated with mesenchymal cell types and ECM remodeling, which were coordinately downregulated by FG-3019 ( Figure 5B ). Similarly regulated transcripts in the 20-day/16-week groups were characteristic of immune cell infiltration and/or have important roles in fibrosis, inflammation (61, 62) , immune cell recruitment (63), tissue destruction (64,65), myofibroblast stimulation, and collagen deposition, fibroblast survival (66) , and EMT and ECM-deposition ( Figure 5 , B and C; Supplementary Table 2, available online) (67) . The abrogation of leukocyte influx All statistical tests were two-sided. RT ¼ irradiation.
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by FG-3019 was reflected in the transcriptome by normalizing markers for mast cells and M2 polarized macrophages, but not M1 macrophages ( Figure 5 , B-D) (68, 69) . The expression data suggest that FG-3019 acted in a concerted manner rather than by blocking a single antifibrotic pathway (Supplementary Results and Supplementary Figures 5 and 6 , available online).
Fibroblasts, Mesenchymal Stem Cells, and TGFbStimulated EMT
In vitro, FG-3019 exhibited little toxicity in clonogenic survival and proliferation assays in primary human endothelial cells (HUVEC, HDMEC), fibroblasts (NHDF, HPF), and A549 lung cancer cells. (Figure 6, A and B) . FG-3019 reduced constitutive (100 mg/ mL: 68.3%, SD ¼ 6.4%, P ¼ .007; 30 mg/mL: 38.2%, SD ¼ 7.8%, P ¼ .03) and TGFb-stimulated HPF migration (30 mg/mL: 58.1%, SD ¼ 6.7%, P ¼ .01) ( Figure 6C ). It attenuated TGFb-stimulated differentiation or EMT with reduced expression of a-SMA and collagen IV protein in HPF and A549 cells ( Figure 6D ), and attenuated TGFb induced epithelial-to-mesenchymal phenotype change (data not shown), supporting the hypothesis that CTGF blockade disrupts TGFb-mediated fibrogenesis. FG-3019 did not alter the intrinsic cellular radiosensitivity of endothelial cells, fibroblasts, and A549 lung cancer cells ( Figure 6 , E-H), or human mesenchymal stem cells. It had only mild and subadditive antimigratory and antiproliferative effects when combined with radiation ( Figure 6 , I-K). FG-3019 did not alter the radiation-induced G2 cell cycle block and did not statistically significantly increase apoptosis of MSC ( Figure 6 , L and M). In a coculture proliferation model of human MSC with HPF or endothelial cells (HDMEC), irradiation of MSC, HPF, and HDMEC in the bottom compartment stimulated paracrine MSC and HPF proliferation in the upper compartment, which was inhibited by FG-3019 for HPF but not for MSC. For example, irradiation of MSC stimulated HPF proliferation by 1.9-fold (SD ¼ 0.22-fold, P ¼ .02), which was reduced by FG-3019 to 1.1-fold (SD ¼ 0.13-fold, P ¼ .03) ( Figure 6N ).
Discussion
Transient administration of FG-3019, a human monoclonal antibody to CTGF, attenuated radiation-induced lung remodeling in C57Bl/6 mice and reversed the process after it had initiated. All FG-3019-treated groups demonstrated benefit: Radiationinduced lung remodeling was attenuated, prevented, or reversed (as assessed by histology and longitudinal CT), and the overall health and lifespan of the mice were improved. When FG-3019 treatment started 20 days after the irradiation, most mice (70%) were rescued from death despite having received a lethal radiation dose. 
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CTGF may contribute to multiple aspects of the process of fibrosis. CTGF may directly modulate the formation of myofibroblasts by regulating transdifferentiation of fibroblasts or epithelial cells or indirectly contribute to myofibroblast formation by enabling edema leading to deposition of provisional matrix upon which epithelial cells undergo EMT. CTGF stimulates myofibroblasts to express chemokines and cytokines that recruit leukocytes and regulate their activity. CTGF also stimulates myofibroblasts to deposit and remodel ECM leading to changes in organ structure and function. Our data support this model by showing that FG-3019 reprogrammed fibrogenesis via normalization of the radiation-induced expression of genes involved in inflammation associated with M2 macrophage influx, EMT, myofibroblast activation, remodeling, and ECM deposition. Open questions remain with respect to radiation dose interdependence on the role of M2/M1 polarization changes that might affect inflammation type, vessel permeabilization, and tissue vascularization (70, 71) .
FG-3019 also normalized radiation-induced SMA and osteopontin protein and mRNA expression, suggesting a reduction of fibrotic disease activity because osteopontin has been implicated in fibrogenesis via ERK-dependent signaling and has been suggested as a biomarker for pulmonary fibrosis (72) (73) (74) .
FG-3019 treatment starting 20 days after irradiation achieved the most profound benefits on lung structure and function. Treatment starting two days before/after irradiation, showed smaller benefits, suggesting that CTGF has an important role in radiation response between weeks 9 and 11 after irradiation, when early FG-3019 administration stopped, but was ongoing in the 20-day group.
FG-3019 two-day pretreatment resulted in longer survival than FG-3019 starting two days after irradiation despite the largely overlapping eight-week administration periods. One possible explanation is that FG-3019 pretreatment attenuated delayed responses to irradiation by preventing leucocyte influx and edema that allows extravascular fibrin to provide a provisional matrix upon which epithelial cells undergo EMT (60) .
Therapeutic administration of FG-3019 reversed progressive lung remodeling, and lung densities decreased over the eight weeks of FG-3019 administration and remained stable without further treatment for another six months until the experiment was terminated. Similarly most radiologic, histologic, lung function, and health parameters reversed their disease progression. These data demonstrate that transient administration of FG- 
3019 had a durable effect and that the process of fibrosis could be reversed. The relatively modest improvement of survival in certain groups may have resulted from the early timing of the treatment or cumulative irreversible lung and/or cardiac toxicity already present at the time of treatment initiation (FG-3019 16 weeks).
Complex homeostatic processes like fibrogenesis are regulated by signaling networks controlled by positive and negative regulatory elements (51, (75) (76) (77) . Our data suggest that CTGF is a mediator of the shift from acute inflammation to a chronic fibrogenic inflammatory program, consistent with the hypothesis proposed by Kular (78) that CCN proteins are modulators of inflammation. Exposure to FG-3019 for only two weeks was sufficient to normalize the gene expression pattern and reprogram fibrotic processes.
In vitro, FG-3019 effects were modest, with no influence on the intrinsic radiosensitivity of cells. However, FG-3019 exhibited antimigratory and antiproliferative effects in fibroblasts/MSCs and attenuated TGFb-stimulated differentiation, constituting mechanisms associated with fibrotic processes (79) . The relative resistance of mesenchymal stem cells to FG-3019 and the preservation of MSC recruitment and paracrine stimulation upon radiation might be relevant for the putative regenerative function of MSC after radiation-induced lung damage (53, 79, 80) Our study is not without limitations. We used only one eight-week FG-3019 administration scheme and one large single radiation dose, and neither dose dependence nor different radiation dose fractionations were examined. The complicated interdependence with heart damage also remains to be elucidated.
Overall, the data on blocking CTGF in a mouse model of radiation-induced lung toxicity are encouraging. The radiationinduced fibrosis model is a relevant trauma that initiates a series of events over almost one year that result in fibrosis and mimic what occurs in humans after irradiation. Transient administration of FG-3019 to irradiated mice prevented and reversed lung remodeling, preserved lung function, and provided a survival benefit. The monoclonal human antibody to CTGF may represent a promising new strategy to prevent, attenuate, 
or reverse radiation-induced lung toxicity. The robustness and the magnitude of the beneficial effects provide translational relevance with potential for clinical transfer. FG-3019 is in clinical development in several indications, including idiopathic pulmonary fibrosis and pancreatic cancer. Our results indicate that CTGF plays an important role in radiation-induced lung toxicity and that blocking CTGF using FG-3019 could benefit patients undergoing radiotherapy in the thorax or may benefit patients with other forms of therapy-induced or idiopathic fibrotic diseases.
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